GU Cancers 2018 | Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC

The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the sequencing and uses of enzalutamide are being explored, in order to maximize its utility. In this interview, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the exciting head-to-head prospective comparator trial of enzalutamide vs. abiraterone acetate plus prednisone for M1 CRPC patients prior to receiving chemotherapy, which assessed tolerability in a real-world setting. Dr Shore covers the aims, design and interesting results of the study so far. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.